The emergence of GLP-1 drugs, initially developed for Type 2 diabetes, has revolutionized weight management, catapulting medications like Ozempic, Wegovy, and Zepbound into the spotlight. Zepbound (tirzepatide), specifically formulated and FDA-approved for weight management and obstructive sleep apnea, represents a significant advancement in this field.
Understanding Aetna's Stance on Weight Loss Drug Coverage
Aetna, like many insurance providers, offers a variety of benefits plans, each with its own policies regarding prescription drug coverage. While some Aetna plans may include Zepbound as a preferred drug, increasing the likelihood of coverage, the specifics depend on the individual plan and the patient's medical indication.
Prior Authorization and Step Therapy
Many Aetna plans require providers to complete a prior authorization process to ensure that the prescribed drug aligns with the plan's covered criteria. This may involve the prescribing doctor submitting additional documentation or a requirement for the patient to try and fail other medications, such as metformin, phentermine, or bupropion, before Zepbound is considered (a process known as step therapy). Additionally, there might be limitations on the medication strength or the quantity that can be dispensed. According to Dr. Supriya Rao, MD, a gastroenterologist and managing partner at Integrated Gastroenterology Consultants, prior authorization is often required, occurring in approximately 50% or more of cases.
Mounjaro vs. Zepbound: Understanding the Difference
It's important to distinguish between Mounjaro and Zepbound, both of which contain tirzepatide. While both medications can aid in weight and blood glucose management, Mounjaro is solely approved for Type 2 diabetes, whereas Zepbound is approved for both weight loss and obstructive sleep apnea.
Meeting Coverage Criteria
Aetna members must meet specific criteria to be eligible for Zepbound coverage. Doctors specializing in weight loss or those familiar with Aetna's specific rules can assist patients in fulfilling these requirements, thereby streamlining the approval process. It's crucial to remember that insurance companies can modify their criteria at any time, and individuals are responsible for staying informed about their plan's formulary rules. Physicians with specialized training in obesity or lifestyle medicine may also be valuable resources for navigating insurance regulations. Dr. Rao emphasizes the importance of understanding your plan's rules, tiers, and prior authorization requirements before seeking a Zepbound prescription. She also incorporates cooking classes and a lifestyle medicine curriculum into her practice.
Read also: Benefits of couples massage detailed
Navigating Costs Without Full Insurance Coverage
Even with insurance coverage, patients may still encounter out-of-pocket expenses for Zepbound, as formularies typically classify medications into different tiers. Brand-name drugs like Zepbound often fall into higher tiers, resulting in a portion of the cost being borne by the patient.
Alternative Payment Options
For individuals without insurance, those whose insurance doesn't cover Zepbound, or those preferring to pay out-of-pocket, several options can make the medication more affordable. Insurance coverage saves Americans billions of dollars on medications every year, and while it’s a solid method for saving money on Zepbound, there are ways to make it more affordable. SingleCare coupons, for example, can significantly reduce the cost of Zepbound. Dr. Rao often recommends the Lilly Direct program, which enables patients to purchase medications directly from the company at a discounted rate. Additionally, coupon codes and patient assistance programs can further offset costs. Eli Lilly also offers a Zepbound savings card for eligible individuals with partial insurance coverage, potentially reducing the out-of-pocket cost to $25 per month.
Aetna's Clinical Policy Bulletins: A Guide to Coverage Decisions
Aetna's Clinical Policy Bulletins (CPBs) serve as a resource for administering plan benefits but do not constitute medical advice. These bulletins reflect Aetna's assessment of whether certain services or supplies are medically necessary, experimental, investigational, unproven, or cosmetic, based on a review of available clinical information and evidence-based guidelines.
Understanding the Scope of CPBs
It's important to note that CPBs are regularly updated and subject to change. They are designed for use by Aetna's professional staff in making clinical determinations related to coverage decisions. Members should review these bulletins with their healthcare providers to fully understand Aetna's policies.
Appealing Coverage Decisions
Aetna provides members with the right to appeal coverage decisions and may offer an opportunity for an independent external review of coverage denials based on medical necessity or regarding the experimental and investigational status of a service or supply.
Read also: How digestive health affects weight loss
Aetna's Coverage Criteria for Weight Management Drugs
Aetna's coverage criteria for chronic weight management drugs, including Saxenda, Wegovy, and Zepbound, are outlined in their Pharmacy Clinical Policy Bulletins. These criteria vary depending on the patient's age and specific circumstances.
Chronic Weight Management in Adults
To be eligible for coverage, adult patients must be 18 years of age or older and have participated in a comprehensive weight management program that includes behavioral modification, a reduced-calorie diet, and increased physical activity for at least 6 months prior to using drug therapy. Additionally, the patient must have a baseline body mass index (BMI) greater than or equal to 35 kg/m2.
Chronic Weight Management in Pediatrics
For pediatric patients aged 12 to 17 years, Aetna may grant authorization for Saxenda or Wegovy when the patient has participated in a comprehensive weight management program for at least 6 months and meets specific BMI and body weight criteria.
Risk Reduction of Major Adverse Cardiovascular Events
Aetna may authorize Wegovy for adults with established cardiovascular disease and either obesity or overweight to reduce the risk of major adverse cardiovascular events, provided that the patient meets specific criteria, including a baseline BMI greater than or equal to 27 kg/m2 and no diagnosis of type 2 diabetes.
Additional Weight Management Medications Covered by Aetna
Aetna's formulary includes a range of weight management medications, each with its own FDA-approved indications and coverage criteria.
Read also: Weight Loss Meds & BCBS
Short-Term Weight Loss Medications
Aetna covers short-term weight loss medications like Adipex-P (phentermine), Lomaira (phentermine), and benzphetamine for patients with a BMI greater than or equal to 30 kg/m2, or greater than or equal to 27 kg/m2 in the presence of other risk factors.
Long-Term Weight Loss Medications
For chronic weight management, Aetna covers medications like Contrave (naltrexone/bupropion extended-release), Qsymia (phentermine/topiramate extended-release), Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide), each with its own specific criteria and limitations of use.
Important Considerations
Aetna's plan benefit descriptions may exclude services and supplies for or related to the treatment of obesity or for diet and weight control. In such cases, claims for weight reduction medications and physician supervision of weight reduction programs may be denied.
Weight Reduction Counseling
Aetna considers up to a combined limit of 26 individual or group visits by any recognized provider per 12-month period as medically necessary for weight reduction counseling in adults who are obese (BMI greater than or equal to 30 kg/m2).
The Role of Lifestyle Modifications
Weight reduction medications should be used as an adjunct to caloric restriction, exercise, and behavioral modification, when these measures alone have not resulted in adequate weight loss.